A Randomized, Double-blind, Placebo-controlled, Japan Local Phase II Clinical Study Comparing Eltrombopag Monotherapy Versus Placebo in Adult Lower-risk Myelodysplastic Syndromes (MDS) Patients With Platelet Transfusion Dependence
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Eltrombopag (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Planned primary completion date changed from 26 Apr 2025 to 24 Apr 2025.
- 27 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2024 Planned End Date changed from 28 Feb 2027 to 9 Dec 2026.